HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU)

研究临床试验单位(CURE CTU)中代表不足人群的艾滋病毒中心将是 由美国大陆五个经验丰富且成功的临床研究网站(CRS)组成。 第六个新的CRS位于华盛顿特区的儿童国家医疗中心。每一个CRSS都有 &gt；20年从事孕妇、婴儿、儿童、青少年和 感染艾滋病毒的年轻人和有感染艾滋病毒风险的年轻人。每个艾滋病毒治愈CRSS都位于48个县或 在华盛顿特区，美国总统结束 艾滋病毒流行。CURE CTU管理层位于加州大学圣地亚哥分校；斯蒂芬博士 A.斯佩克特将担任首席调查员。这六个CRSS位于贝勒学院 德克萨斯州休斯敦的医学/德克萨斯儿童医院，伊利诺伊州芝加哥的罗伯特·H·卢里儿童医院， 西北大学、圣裘德儿童研究医院和田纳西健康大学 田纳西州孟菲斯科学中心，迈阿密大学，霍尔茨儿童医院，佛罗里达州迈阿密，国家儿童医院 华盛顿特区医学中心和加州大学圣地亚哥分校。治愈CTU是 只有一个单位专门专注于对孕妇、妇女、儿童、青少年和 美国大陆25岁以下的年轻人通过NIAID提供资金。具体目标 解决NIAID提议的四个网络中的许多目标高优先领域。目标1：确定 在没有抗逆转录病毒疗法的情况下减少宿主和控制艾滋病毒复制的新颖和持久的干预措施(ART-- 自由缓解)(ACTG目标1和IMPAACT目标2)。目标2：孕产期妇女的先进艺术 对于艾滋病毒，以优化孕产妇和婴儿的健康结果，并加快评估(PK、安全性、抗病毒药物 为孕妇、婴儿、儿童和儿童提供有效和持久的抗逆转录病毒药物 青少年艾滋病毒携带者(艾滋病综合防治方案目标1)。目标3：设计和进行广谱中和抗体的研究 (BNAbs)，单独和联合使用，以及用于预先暴露的长效抗逆转录病毒药物和给药系统 预防(PrEP)(ACTG目标2、HPTN目标1、IMPAACT目标1)。目的4：调查HIV疫苗接种情况。 暴露和未暴露的婴儿诱导广泛的免疫反应，包括广谱中和抗体 (HVTN目标4)。具体目标5：设计和开展评价多用途预防技术的研究 同时预防艾滋病毒和怀孕、性传播感染或阿片依赖(HPTN目标 2)。目标6：确定预防和管理并发症的最佳可行方法 婴幼儿、儿童、青少年和孕产期HIV感染的合并感染及治疗 妇女(IMPAACT目标4)。目标7：预防或改善艾滋病毒相关非传染性共患病的治疗 艾滋病毒携带者/非艾滋病毒携带者的发病率和治愈乙肝病毒感染的评估策略(ACTG目标4， HVTN目标1)。

The HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU) will be comprised of five highly experienced and successful Clinical Research Sites (CRS) within the continental U.S. and a sixth new CRS located at Children’s National Medical Center in Washington, DC. Each of the CRSs has >20 years of experience conducting clinical research in pregnant women, infants, children, adolescents and young adults with and at-risk for HIV infection. Each of the HIV CURE CRSs is located in one of 48 counties or in Washington DC, geographic locations that have been targeted by the U.S. President’s initiative to end the HIV epidemic. The CURE CTU management is located at the University of California San Diego; Dr. Stephen A. Spector will serve as the Principal Investigator. The six CRSs are located at Baylor College of Medicine/Texas Children’s Hospital in Houston, TX, Ann & Robert H. Lurie Children’s Hospital of Chicago, IL, Northwestern University, St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center in Memphis, TN, University of Miami, Holtz Children’s Hospital, Miami, FL, Children’s National Medical Center in Washington, DC, and the University of California, San Diego, CA. The CURE CTU is the only unit specifically focused on research in pregnant women, women, children, adolescents and young adults less than 25 years in the continental U.S. funded through NIAID. The Specific Aims address many of the targeted high priority areas of the four NIAID proposed Networks. Aim 1: Identify novel and durable interventions to reduce reservoirs and control HIV replication in the absence of ART (ART- free remission) (ACTG Aim 1 and IMPAACT Aim 2). Aim 2: Advance ART of pregnant and postpartum women with HIV, to optimize maternal and infant health outcomes, and accelerate the evaluation (PK, safety, antiviral efficacy), licensure and optimal use of potent and durable ARVs for pregnant women, infants, children and adolescents with HIV (IMPAACT Aim 1). Aim 3: Design and conduct studies of broadly neutralizing antibodies (bnAbs), alone and in combination, and long-acting antiretroviral agents and delivery systems for pre-exposure prophylaxis (PrEP) (ACTG Aim 2, HPTN Aim 1, IMPAACT Aim 1). Aim 4: To investigate vaccination of HIV- exposed and unexposed infants to induce broad immune responses including broadly neutralizing antibody (HVTN Aim 4). Specific Aim 5: Design and conduct studies to evaluate multipurpose prevention technologies that concurrently prevent HIV and pregnancy, sexually transmitted infections or opioid dependence (HPTN Aim 2). Aim 6: Determine optimal and feasible methods for the prevention and management of complications and co-infections of HIV infection and their treatment in infants, children, adolescents and pregnant and postpartum women (IMPAACT Aim 4). Aim 7: Prevent or improve the treatment of HIV-related non-infectious co- morbidities and evaluate strategies to cure hepatitis B virus infection in people with/without HIV (ACTG Aim 4, HVTN Aim 1).